The RD-Connect project received six-years funding (2012 - 2018) from the European Union, under the Seventh Framework Programme (FP7) grant, to create a unique infrastructure for rare disease research free to use by scientists and clinicians in Europe and around the world.
RD-Connect is a collaborative work of partners based in Europe and beyond.
As a member of the International Rare Diseases Research Consortium (IRDiRC), RD-Connect contributes to research, improving diagnostics and development of new therapies for the rare disease patients worldwide.
To ensure protection of patient privacy without compromising research and drug discovery, our team of experts on ethics, legal and social issues provides guidance to researchers and work on the most appropriate models for data sharing.
Rare disease patients and their representatives work in RD-Connect as well, to help other project members do the work in the most patient-centered and beneficial way.
For more details on the goals and achievements of RD-Connect, read the summaries of our periodic activity reports.